Research programme: fibroblast growth factor receptor monoclonal antibodies - Eli LillyAlternative Names: IMC-D11
Latest Information Update: 07 Dec 2015
At a glance
- Originator ImClone Systems
- Developer Eli Lilly
- Class Monoclonal antibodies
- Mechanism of Action Type 1 fibroblast growth factor receptor antagonists; Type 3 fibroblast growth factor receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Haematological malignancies; Solid tumours